O'Brien M, Paz-Ares L, Marreaud S, Dafni U, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022 Sep 9. pii: S1470-2045(22)00518.
PMID: 36108662